In Brief: Cardiovascular Dynamics
This article was originally published in The Gray Sheet
Executive Summary
Cardiovascular Dynamics: FDA approves PMA supplement for its FACT-22 (Focus Angioplasty Catheter Technology) and ARC-22 (Active Response Catheter) coronary balloon angioplasty catheters. The products feature longer balloon inflation lengths (22 mm), "which expand the clinical applications and potential market" for CVD's Focus technology, the company says. CVD gained approval in January for the original version of its FACT catheter; an original version of the ARC was approved in June. CVD's Focus technology provides users "both low and high balloon inflation pressures within a single catheter," the company says. CVD plans to launch the new FACT-22 and ARC-22 versions at the scientific sessions of the American Heart Association in November...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.